Grünenthal to buy NebidoTM testosterone treatment from Bayer for €500m
European Pharmaceutical Review
JULY 18, 2022
Nebido is also patented until March 2024 in the European Union and until May 2027 in the United States. The deal is expected to close by the end of 2022, subject to approval by the relevant competition authorities. The long-acting injectable treatment for testosterone deficiency has been commercially approved in more than 80 countries.
Let's personalize your content